FDA Approves Unknown Drug — MSN

# FDA Approves ANDA for MSN The FDA has approved ANDA 211135 for MSN as of September 1, 2022, potentially expanding the company's portfolio in the generic drug market. The approval could strengthen MSN's competitive position and provide additional revenue opportunities, though market impact will depend on the therapeutic category and competitive landscape of the approved medication.